JDP-205
Phase 3- Indications
- Acute allergic reactions
Company intelligence / Profile preview
JDP Therapeutics was a privately held specialty pharmaceutical company focused on developing small molecule therapeutics for life-threatening diseases with significant unmet medical needs, primarily targeting hospital and acute care settings. Its lead product candidate, QZYTIR™ (IV cetirizine), successfully completed a pivotal Phase III trial for the treatment of acute urticaria—an area with little innovation in over six decades. The company’s approach involved repurposing or reformulating proven chemical entities to address new indications or improve dosage forms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JDP Therapeutics.